22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise
November 27, 2023
Ryan Allway November 27th, 2023 News, Top News, Top Story Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash Requirements BUFFALO, N.Y., Nov. 27, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company” or “22nd Century”), a leading biotechnology company focused on... Read more
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma
November 8, 2022
Ryan Allway November 8th, 2022 News, Top News REHOVOT, Israel and BETHESDA, MD, Nov. 8, 2022 /PRNewswire/ — CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related medicine, announced today that it has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company,... Read more
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Second Quarter 2022
August 9, 2022
Ryan Allway August 9th, 2022 News, Top News Strong Chicago Pilot Exceeded Expectations, Accelerates VLN® Expansion in Colorado Accretive GVB Biopharma Acquisition Doubles Corporate Revenue and Expands Market Leading Hemp/Cannabis Capabilities Second Quarter Net Sales $14.5 Million, Up 73% from the Second Quarter 2021 Strengthened Balance Sheet with $35 Million... Read more
